STANOZOLOL 1 ml/ 100 mg
Stanozolol USP29, Ph.Eur.5.5, Supermicronized grade Suspension Injectable
Formula: C22H36N20 (CAS-10161 -34-9)
STAN 100®, brand of Stanozolol suspension injection, is an anabolic steroid, a synthetic derivative of testosterone. Each ml. contains 100 mg Stanozolol USP29. Ph.Eur.5.5, supermicronized grade. It is designated chemically as 17- methyl-2'//-5a-androst-2eno[3,2-c]pyrazol-17|3-ol.
STAN 100® is a sterile solution of Stanozolol USP in Sodium phosphate dibasic, Polysorbate 80, Sodium merthiolatc, Sodium chloride, Sterilized waterfor injection.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved.The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. They suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
STAN 100® has been found to increase low-density lipoproteins and decrease high-density lipoproteins.These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment.
Hereditary angiocdema (HAE) is an autosomal dominant disorder caused by a deficient or nonfunctional Cl esterase inhibitor (Cl INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract.
In small scale clinical studies, STAN 100® was effective in controlling the frequency and severity of attacks of angiotedema and in increasing serum levels of Cl INH and C4. STAN 100® is not effective in stopping HAE attacks while they are under way. The effect of STAN 100® on increasing serum levels of Cl INH and C4 may be related toan increase in protein anabolism.
INDICATIONS AND USAGE:
-General deterioration status, different origin slimness, anorexia not responding to treatment, convalescence, chronicand weakening diseases. -Nephrotic and asthmatic syndromes, rheumatoid arthritis etc., for counteracting catabolic effects produced by corticosteroids.
-As coadjuvant in the treatment of decubitus ulcers, bone fractures of slow recovery, osteoporosis, extensive bums, periods before and after a surgical operation.
-In paediatrics, in growth failure in length and weight, somatic hypoevolutism.distrophia and immaturity.
STAN 100® is an aqueous suspension formulated for a prolonged absorption and with no local irritative effects. Its use is preferable provided that the doctor considers separate in time parenteral administrations more safe or more convenientthan oral dairy administration.
Shake the vial before its use.
A diet rich and equilibrated is convenient when the product is being administered. CONTRAINDICATIONS:
The use of STAN 100® is contraindicated in the following:
1 .Carcinoma of the prostate or breast in male patients.
2. Carcinoma of the breast in somefemales.
3. Nephrosis orthe nephrotic phase of nephritis.
4.STAN 100® can cause fetal harm when administered to a pregnant woman.
STAN 100® is contraindicated in women who are or may become pregnant. If this dmg is used during pregnancy, or if the patient becomes pregnant while taking this dmg, the patient should be apprised of the potential hazard to the fetus.
5.Hypersensitivity to stanozolol,